Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Tóm tắt
Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to March 2018 who were tested using fluorescence in situ hybridization within 90 days of diagnosis. We characterized patients as having documented C1As or other high-risk chromosomal abnormalities (HRCAs) as defined by the Revised-International Staging System (R-ISS) such as del(17p), t(14;16), and t(4;14). We used Kaplan-Meier methods to compare overall survival (OS) of patients with or without C1As and stratified log-rank tests (with the presence of HRCAs as a stratifying variable). We used Cox proportional hazards regression models to compare OS, adjusting for age, sex, stage, HRCAs, and type of first-line therapy. Of 3578 eligible patients, 844 (24%) had documented C1As. Compared with patients without C1As, patients with C1As were more likely to have higher stage (R-ISS stage III; 18% vs 12%), to have HRCAs (27% vs 14%), and to receive combinations of proteasome inhibitors and immunomodulatory agents (41% vs 34%). Median OS was lower for patients with C1As (46.6 vs 70.1 months; log-rank P < .001). C1As were independently associated with worse OS (adjusted hazard ratio, 1.42; 95% confidence interval, 1.19-2.69; P < .001), as were older age, higher R-ISS stage, HRCAs, and immunoglobulin A isotype. C1As were associated with inferior OS, independent of other HRCAs, despite greater use of novel therapies. Clinical trials testing newer therapies for high-risk MM should incorporate patients with C1As.
Tài liệu tham khảo
National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 20 August 2019.
Avet-Loiseau, 2013, Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project, Leukemia, 27, 711, 10.1038/leu.2012.282
Manier, 2017, Genomic complexity of multiple myeloma and its clinical implications, Nat Rev Clin Oncol, 14, 100, 10.1038/nrclinonc.2016.122
Palumbo, 2015, Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group, J Clin Oncol, 33, 2863, 10.1200/JCO.2015.61.2267
Sonneveld, 2016, Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood, 127, 2955, 10.1182/blood-2016-01-631200
Marzin, 2006, Chromosome 1 abnormalities in multiple myeloma, Anticancer Res, 26, 953
Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome, Blood, 109, 3489, 10.1182/blood-2006-08-040410
Fonseca, 2006, Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia, 20, 2034, 10.1038/sj.leu.2404403
Scott, 2016, Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: A CIBMTR analysis, Biol Blood Marrow Transplant, 22, 1893, 10.1016/j.bbmt.2016.07.007
Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430
Caltagirone, 2014, Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies, Haematologica, 99, 1611, 10.3324/haematol.2014.103853
Hanamura, 2006, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood, 108, 1724, 10.1182/blood-2006-03-009910
Boyd, 2012, A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial, Leukemia, 26, 349, 10.1038/leu.2011.204
Biran, 2014, Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens, Am J Hematol, 89, 616, 10.1002/ajh.23705
Shah, 2017, Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation, Leuk Lymphoma, 58, 1823, 10.1080/10428194.2016.1260126
Grzasko, 2017, Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group, Leuk Lymphoma, 58, 1, 10.1080/10428194.2016.1272684
Hebraud, 2014, Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients, Leukemia, 28, 675, 10.1038/leu.2013.225
Rajkumar, 2006, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group, J Clin Oncol, 24, 431, 10.1200/JCO.2005.03.0221
Curtis, 2018, Development and validation of a high-quality composite real-world mortality endpoint, Health Serv Res, 53, 4460, 10.1111/1475-6773.12872
Kish, 2014, Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries, J Natl Cancer Inst Monogr, 2014, 236, 10.1093/jncimonographs/lgu020
Facon, 2001, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, 97, 1566, 10.1182/blood.V97.6.1566
Hebraud, 2015, Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience, Blood, 125, 2095, 10.1182/blood-2014-07-587964
Nahi, 2016, Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21, Eur J Haematol, 96, 46, 10.1111/ejh.12546
Schmidt, 2019, Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone, Blood Cancer J, 9, 94, 10.1038/s41408-019-0254-0
Varma, 2020, Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: Propensity score matched analysis, Biol Blood Marrow Transplant, 26, 665, 10.1016/j.bbmt.2019.12.726
Christofferson, 2019, Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis [abstract], Blood, 134, Abstract 1805, 10.1182/blood-2019-132152
Avet-Loiseau, 2010, Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p), J Clin Oncol, 28, 4630, 10.1200/JCO.2010.28.3945
Sonneveld, 2012, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial, J Clin Oncol, 30, 2946, 10.1200/JCO.2011.39.6820
Reece, 2009, Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13, Blood, 114, 522, 10.1182/blood-2008-12-193458
An, 2014, Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value, Haematologica, 99, 353, 10.3324/haematol.2013.088211
Pulte, 2014, Recent improvement in survival of patients with multiple myeloma: variation by ethnicity, Leuk Lymphoma, 55, 1083, 10.3109/10428194.2013.827188
Ailawadhi, 2012, Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups, Br J Haematol, 158, 91, 10.1111/j.1365-2141.2012.09124.x
Ailawadhi, 2018, Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities, Cancer, 124, 1710, 10.1002/cncr.31237
Costa, 2015, Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma, Biol Blood Marrow Transplant, 21, 701, 10.1016/j.bbmt.2014.12.024
Jain, 2017, Racial differences in disease characteristics: Understanding multiple myeloma in Hispanics [abstract], Blood, 130, 10.1182/blood.V130.Suppl_1.864.864
Kaur, 2018, Multiple myeloma in Hispanics is associated with better survival than non-Hispanic African Americans and Whites: Analysis from a large single center minority rich cohort [abstract], Blood, 132, 10.1182/blood-2018-99-120282
Kumar, 2019, A novel approach to risk stratification in multiple myeloma using ISS stage and FISH [abstract], Blood, 134, 10.1182/blood-2019-130639